Clinical Trial

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Study acronym: NORLIGHT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?
Protocol Amendment History 4 changes
notable Trial sites expanded: 23 -> 26 locations 2026-08-07
critical Primary endpoint(s) modified 2026-07-17
notable Trial sites expanded: 16 -> 21 locations 2026-06-09
notable Trial sites expanded: 13 -> 16 locations 2026-05-09
Trial Details
NCT Number NCT07284667
Lead Sponsor ACADIA Pharmaceuticals Inc.
Conditions Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
Enrollment 153 participants
Start Date 2025-11-14
Primary Completion 2027-08 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-06